within Pharmacolibrary.Drugs.R_RespiratorySystem.R05D_CoughSuppressantsExclCombinationsWithExpectorant.R05DB15_Zipeprol;

model Zipeprol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 1.633333333333333e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.003,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Zipeprol</td></tr><tr><td>ATC code:</td><td>R05DB15</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.014</td><td>L/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Zipeprol is a centrally acting antitussive (cough suppressant) that was previously used for the symptomatic relief of cough. It is no longer approved or widely used due to its potential for abuse and adverse effects including fatal intoxications.</p><h4>Pharmacokinetics</h4><p>No original human pharmacokinetic data for zipeprol is directly available in published literature. The following parameters are rough theoretical estimates based on similar antitussive agents.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R05DB15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Zipeprol;
